Brief: Usana Health Sciences Sees Q3 Sales $265 Mln TO $270 Mln

USANA Health Sciences

16/09/2021 21:20

Sept 16 (Reuters) - USANA Health Sciences Inc  USNA.N :
    * USANA HEALTH SCIENCES PROVIDES PRELIMINARY THIRD QUARTER
RESULTS
AND UPDATES FISCAL YEAR 2021 OUTLOOK; INCREASES SHARE REPURCHASE
AUTHORIZATION
    * SEES Q3 EARNINGS PER SHARE $1.28 TO $1.33
    * SEES Q3 SALES $265 MILLION TO $270 MILLION
    * SEES FULL-YEAR 2021 NET SALES $1.18 BILLION TO $1.20
BILLION
    * Q3 SALES HAVE BEEN SOFTER THAN ANTICIPATED, LARGELY
BECAUSE OF
INCREASED DISRUPTIONS AND LOCKDOWNS DUE TO PANDEMIC
    * SEES FULL-YEAR 2021 DILUTED EPS TO BE $5.80 TO $6.00
    * LESS FAVORABLE CURRENCY EXCHANGE RATES ALSO IMPACTED Q3,
CONTRIBUTED TO FY ADJUSTED SALES OUTLOOK
    * BOARD INCREASED SHARE REPURCHASE AUTHORIZATION TO $150
MILLION
    * USANA HEALTH SCIENCES - IN SOME MARKETS, WE HAVE DELAYED
INTRODUCTION OF NEW PRODUCT OFFERINGS UNTIL 2022

Source text for Eikon:  ID:nBw9Jf5t8a 
Further company coverage:  USNA.N 

 ((reuters.briefs@thomsonreuters.com;))